Register for our free email digests:
Gilead Sciences, Inc.
http://www.gilead.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gilead Sciences, Inc.
Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs
Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.
Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.
Medicare’s New Codes For Remdesivir, Convalescent Plasma To Be Test Of Real-World, Though Not Real-Time, Data
CMS’s new procedure reimbursement codes will help generate ‘critical information’ on the effectiveness of the COVID products, but will suffer from a ‘claims lag.’
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Arresto Biosciences, Inc.
- Asegua Therapeutics, LLC
- Calistoga Pharmaceuticals, Inc.
- CGI Pharmaceuticals, Inc.
- CV Therapeutics, Inc.
- Cytopia Limited
- EpiTherapeutics
- Eximias Pharmaceutical Corporation
- Myogen
- Nimbus Apollo, Inc.
- Nexstar Pharmaceuticals
- Pharmasset, Inc.
- Triangle Pharmaceuticals
- YM BioSciences Inc. (YMI)
- Kite Pharma, Inc.
- Kite Pharma EU
- T-Cell Factory B.V. (TCF)
- Cell Design Labs, Inc.
- Asegua Therapeutics